Fact CheckerSign in

NCT07907822Not yet recruiting

A Study to Evaluate the Effectiveness and Safety of S-amlodipine-based Monotherapy and Combination Therapy

A Multicenter, Prospective, Observational Study to Evaluate the Effectiveness and Safety of S-amlodipine-based Monotherapy and Combination Therapy in Korean Hypertensive Patients

Source: ClinicalTrials.gov · Last updated 30 Oct 2026

Brief summary (registry, in English)

This study aims to evaluate the effectiveness, safety, and clinical utility as a treatment strategy of the s-amlodipine-based monotherapy, dual combination, and triple combination in patients with hypertension across various stages of blood pressure control in routine clinical practice.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
4528 (estimated)
First submitted
26 Oct 2026
Start date
Nov 2026
Primary completion date
Feb 2029
Lead sponsor
Ahn-Gook Pharmaceuticals Co.,Ltd
NCT number
NCT07907822

What you commit to

  • Study type: Observational
  • Planned participants: 4528
  • From Nov 2026 to the primary completion date, Feb 2029
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • The patients who are contraindicated for the administration of the study drug according to the approved label

Other

  • The patients who meet any of the following exclusion criteria cannot participate in this study.
  • The patients who are pregnant, possibly pregnant, or lactating women = The patients who are judged by the investigator to be inappropriate for participation in this study

Who the study is looking for

  • Patients who voluntarily consent on the informed consent form and understand the study's purpose, methods, and so on
  • Males and females over the age of 19
  • Patients who have been diagnosed with essential hypertension and plan to be treated with S- amlodipine or S-amlodipine/Valsartan or S-amlodipine/Valsartan/Indapamide

Age in the registry: 19 years to - · Sex: All

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.